Genmab A/S stock is up 4.32% since 30 days ago. The next earnings date is Feb 21, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 4 December’s closed higher than November. 67% of analysts rate it a buy.
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases. The company markets DARZALEX, a human monoclonal antibody for the. treatment of patients with multiple myeloma (MM) and ofatumurnab for. multiple sclerosis (CLL) and multiple sclerosis. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers.